The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 11, 2020

Filed:

Dec. 30, 2015
Applicants:

Signpath Pharma Inc., Quakertown, PA (US);

Avanti Polar Lipids, Inc., Alabaster, AL (US);

Inventors:

Peter P. Sordillo, New York, NY (US);

Lawrence Helson, Quakertown, PA (US);

Stephen W. Burgess, Chelsea, AL (US);

Walter A. Shaw, Birmingham, AL (US);

Assignees:

Signpath Pharma, Inc., Sandy, UT (US);

Avanti Polar Lipids, Inc., Alabaster, AL (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/68 (2006.01); A61K 31/12 (2006.01); A61K 9/127 (2006.01); A61K 31/683 (2006.01); A61K 9/00 (2006.01); A61K 47/12 (2006.01); A61K 47/14 (2017.01);
U.S. Cl.
CPC ...
G01N 33/6863 (2013.01); A61K 9/0019 (2013.01); A61K 9/127 (2013.01); A61K 31/12 (2013.01); A61K 31/683 (2013.01); A61K 47/12 (2013.01); A61K 47/14 (2013.01); G01N 2333/523 (2013.01); G01N 2333/525 (2013.01); G01N 2333/545 (2013.01); G01N 2333/5412 (2013.01); G01N 2333/5421 (2013.01); G01N 2333/5428 (2013.01); G01N 2333/55 (2013.01); G01N 2333/57 (2013.01); G01N 2800/24 (2013.01); G01N 2800/52 (2013.01); Y02A 50/385 (2018.01); Y02A 50/387 (2018.01); Y02A 50/397 (2018.01);
Abstract

The present invention includes methods and compositions for ameliorating symptoms or treating one or more adverse reactions triggered by infectious diseases or disease conditions that trigger a widespread release of cytokines in a subject comprising the steps of: identifying the subject in need of amelioration of symptoms or treatment of the infectious diseases or disease conditions that trigger a widespread release of cytokines; and administering one or more pharmaceutical compositions comprising a therapeutically effective amount of a curcumin extract, curcuminoids or synthetic curcumin (S-curcumin) and derivatives thereof, or empty liposomes, dissolved or dispersed in a suitable aqueous or non-aqueous medium sufficient to reduce the level of cytokines in the host.


Find Patent Forward Citations

Loading…